Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)-MedSci.cn

Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Finn, RS; Kudo, M; Merle, P; Meyer, T; Qin, S; Ikeda, M; Xu, R; Edeline, J; Ryoo, BY; Ren, Z; Cheng, AL; Galle, PR; Kaneko, S; Kumada, H; Wang, A; Mody, K; Dubrovsky, L; Siegel, AB; Llovet, J

ANNALS OF ONCOLOGY, 2022; 33 (7): S1401

科室
- - 订阅+
  - 更多科室
工具
服务